BridgeBio Oncology Therapeutics (BBOT) Long-Term Investments (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Long-Term Investments of $136.6 million for Q1 2026, down 30.48% sequentially from $196.5 million in Q2 2025, and up 440699900.0% YoY from N/an in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Long-Term Investments (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $136.6 million in Q1 2026.
- Quarterly Long-Term Investments rose 440699900.0% year-over-year to $136.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.6 million (up 440699900.0% YoY) and the FY2024 annual result came in at $634.0, changed N/A from the prior year.
- Long-Term Investments slipped to $136.6 million in Q1 2026 per BBOT's latest filing, from $196.5 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $196.5 million in Q2 2025 and troughed at $6.0 in Q1 2024.
- A 3-year average of $101.6 million and a median of $136.6 million in 2026 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2025 and 2026: Long-Term Investments gained 4.72% in 2025, then jumped 440699900.0% in 2026.
- Over 3 years, Long-Term Investments stood at $634.0 in 2024, then soared by 30995729.34% to $196.5 million in 2025, then tumbled by 30.48% to $136.6 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $136.6 million, $196.5 million, and $31.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 118.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 118.42 Mn |
| Mar 31, 2026 | 136.62 Mn |
| Jun 30, 2025 | 196.51 Mn |
| Mar 31, 2025 | 31.00 |
| Dec 31, 2024 | 634.00 |
| Sep 30, 2024 | 190.20 Mn |
| Jun 30, 2024 | 187.65 Mn |
| Mar 31, 2024 | 6.00 |